Conference Call and Webcast Scheduled for Friday, February 26 at 4:30 p.m. Eastern Time Conference Call and Webcast Scheduled for Friday, February 26 at 4:30 p.m. Eastern Time
Read this article:
Recro to Report Financial Results for Fourth Quarter And Year-End 2020 on February 26
Related Post
- EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19 - March 1st, 2021
- Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021 - March 1st, 2021
- MacroGenics to Participate in Upcoming Investor Conferences - March 1st, 2021
- Cronos Group Reports 2020 Fourth Quarter and Full-Year Results - March 1st, 2021
- GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis... - March 1st, 2021
- Golden Leaf Holdings Enters into Letter of Intent to Acquire Retail Chain - March 1st, 2021
- TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update - March 1st, 2021
- Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B... - March 1st, 2021
- Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day® - March 1st, 2021
- SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results - March 1st, 2021
- Molecular Templates to Participate in Upcoming Virtual Investor Conferences - March 1st, 2021
- ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American... - March 1st, 2021
- electroCore Inc. Announces Exclusive Distribution Agreement with Medistar Following Regulatory Approval in Australia - March 1st, 2021
- BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce... - March 1st, 2021
- Annual financial report 2020 - March 1st, 2021
- Idorsia submits NDA for clazosentan to Japanese PMDA - March 1st, 2021
- Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial - March 1st, 2021
- Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China - March 1st, 2021
- Orphazyme appoints Christophe Bourdon as Chief Executive Officer - March 1st, 2021
- Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day® - February 27th, 2021
- Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer - February 27th, 2021
- Albireo Spotlights Global Patient Communities on Rare Disease Day - February 27th, 2021
- Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan - February 27th, 2021
- Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE - February 27th, 2021
- Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients - February 27th, 2021
- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization... - February 27th, 2021
- Genetic Technologies Limited Interview to Air on Bloomberg TV in the US on the RedChip Money Report® - February 27th, 2021
- Supernus to Present at Cowen Healthcare Conference - February 27th, 2021
- Innovation Pharma Provides Study Details for Ongoing Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients - February 27th, 2021
- Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany - February 27th, 2021
- UPDATE -- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use... - February 27th, 2021
- GENFIT: Revenues and Cash Position as of December 31, 2020 - February 27th, 2021
- Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab - February 27th, 2021
- Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences - February 27th, 2021
- Orphazyme announces participation in upcoming virtual investor conferences - February 27th, 2021
- NextCure to Host Virtual R&D Update Event on March 4, 2021 - February 27th, 2021
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - February 27th, 2021
- Zomedica Corp. Announces Year End 2020 Financial Results - February 27th, 2021
- Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights - February 27th, 2021
- Quotient Limited Announces Manuel Mendez as Chief Executive Officer - February 23rd, 2021
- AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in pancreatic cancer - February 23rd, 2021
- Notice for the Annual General Meeting of Novo Nordisk A/S - February 23rd, 2021
- Agios to Present at March Investor Conferences - February 23rd, 2021
- Recro Announces Amendment to Athyrium Credit Facility - February 23rd, 2021
- Coya Therapeutics™ Announces Formation of Scientific Advisory Board - February 23rd, 2021
- Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences - February 23rd, 2021
- Kraig Biocraft Laboratories receives its first-ever Spider Silk shipment from its Vietnamese production facility - February 23rd, 2021
- iTeos to Present at Upcoming Investor Conferences in March - February 23rd, 2021
- Study Demonstrates Macrolide-Resistance in S. pneumoniae in the United States Exceeds 25 Percent Threshold Set in Current Community-Acquired Bacterial... - February 23rd, 2021
- BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate Secretary - February 23rd, 2021
- Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference - February 23rd, 2021
- PolyPid to Participate in Upcoming Investor Conferences - February 23rd, 2021
- AgraFlora Organics Announces anticipated First Sales and Revenue for Summer 2021 - February 23rd, 2021
- Adaptive Biotechnologies Launches T-Detect™ COVID, First Clinical T-Cell Based Test for Patients to Confirm Recent or Prior COVID-19 Infection - February 23rd, 2021
- Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021 - February 23rd, 2021
- Black Diamond Therapeutics to Present at Upcoming Investor Conferences - February 23rd, 2021
- Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference - February 23rd, 2021
- European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis... - February 23rd, 2021
- TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with... - February 23rd, 2021
- GBT Announces Participation in Upcoming Investor Conferences - February 21st, 2021
- Assembly Bio Announces Upcoming Investor Events - February 21st, 2021
- RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference - February 21st, 2021
- BridgeBio Pharma and Affiliate ML Bio Solutions Announce Dosing of First Patient in Phase 2 Trial of BBP-418 in Limb Girdle Muscular Dystrophy Type 2i... - February 21st, 2021
- Intercept to Present at Upcoming Investor Conferences - February 21st, 2021
- Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates - February 21st, 2021
- Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® Platform - February 21st, 2021
- Information expressed in the public domain by the Repharm Group is deceptive and contradictory - February 21st, 2021
- Agile Therapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Provide Corporate and Twirla Commercial Updates on... - February 21st, 2021
- CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology - February 21st, 2021
- Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan - February 21st, 2021
- Yield10 Bioscience Announces Warrant Exercises for Proceeds of $3.8 million - February 21st, 2021
- Aeterna Zentaris Announces Closing of $29.7 Million Bought Deal Offering of Common Shares - February 21st, 2021
- Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE, at the AAAAI Annual Meeting - February 21st, 2021
- Ayala Pharmaceuticals Announces $25 Million Strategic Financing - February 21st, 2021
- Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021 - February 21st, 2021
- Tauriga Sciences Inc. Officially Launches Two New Product Offerings on its E-Commerce Platform (www.taurigum.com) - February 21st, 2021
- Iterum Therapeutics to Present in Upcoming Investor Conferences - February 21st, 2021
- Constellation Pharmaceuticals to Participate in the 10th Annual SVB Leerink Global Healthcare Conference - February 21st, 2021
- Anteris Technologies to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference - February 17th, 2021
- AGTC to Present at the OIS Gene Therapy Innovation Showcase on February 18, 2021 - February 17th, 2021
Recent Comments